CD44 is an adhesion molecule that is expressed on hematopoietic cells and has been implicated in the interactions
Introduction
CD44 is a transmembrane glycoprotein expressed by all hematopoietic cells which is best known for its adhesive function binding a number of extracellular matrix components and cellular ligands. 1, 2 However, CD44 is a multi-functional molecule which is also capable of signal transduction and acts as an accessory molecule in lymphocyte activation. [3] [4] [5] Antibodies to CD44 can dysregulate the production of myeloid and lymphoid cells in long-term bone marrow cultures with some CD44 antibodies inhibiting hematopoietic cell output while others enhance it. 6 Taken together, these data indicate that CD44 is important for the interaction of hematopoietic cells with the bone marrow microenvironment and is involved in the regulation of hematopoietic cell production. [7] [8] [9] CD44 can occur in many isoforms derived from a single gene by alternative mRNA splicing. The gene consists of 20 exons, nine of which encode the hematopoietic or standard form of the molecule (CD44H), one encodes an alternative and truncated cytoplasmic tail, while the remainder can be inserted in various combinations into the membrane proximal region of the extracellular domain of the protein giving rise to variant isoforms (CD44v). 10 Hematopoietic cells predominantly express CD44H although variant forms containing exons v6, v8, v9 and v10 have been detected in peripheral blood mononuclear cells and in a number of myeloid cell lines 11 and CD44 variants containing v6 and v9 are also transiently expressed during peripheral blood T cell activation. [12] [13] [14] Altered CD44 variant expression has been demonstrated in a number of malignancies including non-Hodgkin's lymphoma, myeloma and cancers of the breast, gastric mucosa and colon. [15] [16] [17] [18] [19] [20] Although the nature of the changes in CD44 variant expression have not been consistent in all tumor types the expression of variants containing exon v6 have been associated with tumor dissemination in a number of these tumors. [19] [20] [21] Exon v3 has been associated with increased bone marrow infiltration in Burkitt's lymphoma. 22 Recent studies have demonstrated elevated levels of exon v10 expression in chronic and acute myeloid leukemias and a correlation between the expression of exon v6 and poor prognosis in acute myeloid leukemia. 23, 24 Considering the importance of CD44 in the regulation of hematopoietic cell growth and differentiation it is likely that the expression of CD44 variants could influence the biology of acute leukemias. In this paper we examined the expression of CD44 variant exons in acute myeloid leukemia by flow cytometry using exon specific antibodies and by RT-PCR and Southern blotting.
Methods

Cells
Blasts were obtained from peripheral blood or bone marrow samples from 30 patients with AML at diagnosis or relapse. Patient details are given in Table 1 . Normal bone marrow samples were obtained from allogeneic bone marrow donors while normal volunteers provided peripheral blood samples. All samples were obtained in accordance with Institutional Ethics Committee Guidelines. Bone marrow and peripheral blood mononuclear cells were purified on Ficoll-Hypaque as previously described 25 and in some cases cryopreserved. Normal CD34
+ cells were isolated from normal allogeneic bone marrow mononuclear cells. For flow cytometry experiments CD34 + cells were purified from bone marrow mononuclear cells by direct FACS sorting using HPCA-2 PE as the labeling antibody. For RT-PCR experiments CD34 + cells were purified using a combination of a MACS column enrichment and FACS sorting as previously described 26 and were 99.7 ± 0.3% (n = 4) pure on re-analysis. Briefly, CD34
+ cells were enriched via a MACS column using QBEND10 biotin (a kind gift from Prof M Greaves, Leukaemia Research Fund Centre, Institute of Cancer Research, London, UK) and streptavidin conjugated immunomagnetic beads (Becton Dickinson, Mountain View, CA, USA) then purified by sorting on a FACS Vantage cell sorter. 
RT-PCR
Total RNA was extracted from between 1 and 10 × 10 6 cells using a total RNA extraction kit (Integrated Sciences, Sydney, Australia) according to the manufacturer's instructions. Airdried pellets were dissolved in 20 l of H 2 O, of which 5-10 l was used for the preparation of cDNA using an oligo-dT primer (Life Technologies, Melbourne, Australia) and Moloney murine leukemia virus reverse transcriptase (Amersham, Buckinghamshire, UK). The cDNA was prepared in the presence of placental RNase inhibitor (Amersham) at 37°C for 45 min. One-4 l of cDNA was amplified by Taq polymerase (Amersham) in a final volume of 50 l using primers homologous to positions 513-540 and 936-963 of the published sequence. 27 Samples were amplified for 25 cycles using a Touchdown PCR with annealing temperatures starting at 60°C and decreasing by 2°C each cycle for five cycles then maintained at 50°C for a further 20 cycles. Melting and extension temperatures were 95°C and 72°C throughout. The amplification products were separated on a 1.2% agarose gel and visualized by ethidium bromide staining under a UV light source. In some cases a primer directed against an individual exon was used in combination with a primer from the constant region, thereby amplifying only cDNAs which contain the selected exon.
Southern blotting
CD44 PCR products were transferred on to nylon membranes (Hybond N+, Amersham) for Southern blotting. Positive controls were generated by PCR amplification of genomic DNA using the following primer pairs: v4 forward/v5 reverse; v6 forward/v7 reverse; v7 forward/v8 reverse; v9 forward/v10 reverse. These PCR products contained two exons and the intervening intron sequence and were 0.7, 2, 2.5 and 1.5 kb, respectively. Products containing the exon being tested were used as positive control while those lacking the test exon were used as negative controls. Positive and negative controls were included on all filters. Hybridization was performed in 0.5 M phosphate buffer pH 7.5 containing 1 mM EDTA (Hyb buffer) and 7% SDS overnight at 65°C. Filters were thoroughly washed with Hyb buffer containing 5%, then 1% SDS at 60°C. Membranes were exposed to X-ray film to reveal labeled bands.
Cloning of CD44 variant containing cDNAs
Exon v6 containing cDNAs were PCR amplified using exon specific primers. Two reactions were performed, one using the exon v6 specific forward primer and the reverse primer from the constant region of CD44 and second reaction using the exon v6 specific reverse primer and the forward primer from the CD44 constant region. The forward reaction for exon v6 produced multiple bands while the reverse reaction demonstrates that exon v6 is attached to the constant region of CD44 without other exons in both cases. The products obtained from the forward reaction were cloned, sequenced and re-amplified individually. DNA containing the CD44 variant region and the adjoining CD44 constant regions were produced using the overlap extension of the products from the variant exon forward and reverse reactions.
Results
Expression of CD44 variants by flow cytometry
Normal peripheral blood lymphocytes and bone marrow mononuclear cells were examined for their expression of the CD44 variants by flow cytometry. All normal peripheral blood and bone marrow samples were negative for all variants tested. CD34
+ cells isolated from normal bone marrow were also negative for all variant exons tested by flow cytometry.
The expression of CD44 variant exons, by blasts from patients with AML, as determined by flow cytometry is shown in Table 2 . Using flow cytometry, it is not possible to determine whether the exon being examined is expressed in isolation or in combination with other exons. Therefore, the data in this section refer to the total level of variant exon expression. Cases were considered to be positive if 10% or more of the cells were positive. Protein expression of exon v3 was detected in two of 16 cases (13%), exon v4 on 18 of 27 cases (67%), exon v5 on five of 27 cases (19%), exon v6 on two of 27 cases (7%), exon v7 on 17 of 26 cases (65%) and exon v10 on 0 of 27 cases (0%). Since normal bone marrow and peripheral blood mononuclear cells were negative for CD44 variants by flow cytometry and most cases of AML consisted of greater than 90% blasts, it is unlikely that CD44 variants detected by flow cytometry were on contaminating nor- Table 2 Expression of CD44 variant exons as determined by flow cytometry (Figure 1a and b) . The exception to this was v4, which, in 10 of the 18 positive cases demonstrated a distinct subpopulation of v4 positive cells (Figure 1a) . In five cases, two color labeling for CD44 variants and a leukemic cell marker (CD34 in four cases and CD13 in one case) (Figure 1c ) confirmed the expression of CD44 variants on the leukemic population.
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Expression of CD44 variant mRNA using RT-PCR and Southern blotting
In both normal and leukemic bone marrow and peripheral blood samples the dominant RT-PCR product was 450 bp in size representing CD44H, which lacks all inserted exons. The exon-containing products were not visible by ethidium bromide staining in most cases ( Figure 2 ).
Normal peripheral blood, bone marrow and CD34
+ cells: Southern blotting of RT-PCR products revealed the presence of several variant exons in all normal peripheral blood, bone marrow and CD34
+ samples (Figures 3 and 4) . The pattern of CD44 variant exon expression was the same for normal bone marrow and peripheral blood lymphocytes. Exons v4, v5, and v7 were not detected. Exon v3 and exon v6 were each identified in single products, both of approximately 550 bp. This size indicates that exon v3 and exon v6 were the only variant exons present in these products and were expressed independently of each other. Exons v8, v9 and v10 were detected in three separate bands. These were approximately 650 bp, 750 bp and 1150 bp in size. The smallest species containing exon v10 represents CD44R2 that includes exon v10 alone. Exons v8 and v9 were also detected in a 650 bp band. It is possible that these exons are occurring in combination with each other but in the absence of exon v10. It is difficult to be certain which exons are combined with v10 in the 750 bp species but it is most likely that v8 and/or v9 are combined with v10. The larger band of approximately 1150 bp contains v8, v9 and v10 along with at least two other exons. This band is very faint and it is possible that the remaining exons failed to be detected due to variations in labeling efficiencies of different probes. Interestingly, the product for CD44R1 which contains exons v8, v9 and v10 was not detected, although this product was clearly detected in KG1 cells which are known to express this variant (data not shown). 11 
Normal CD34
+ cells purified from normal bone marrow were also examined for CD44 variant expression by RT-PCR and Southern blotting (Figure 4 ). Exons v3, and v10 were detected in all samples tested. Exons v3 and v10 were inserted as single exons in the absence of any other exons. Exon v6 was detected in only one of four marrows and again was not combined with other exons. Faint bands were also detected in three of the four marrows for exon v8. The size of this band suggested that exon v8 was expressed alone.
AML cells:
Twenty-four cases of AML were similarly examined by RT-PCR and Southern blotting (Figure 2 ). The product containing exon v3 alone detected in normal hematopoietic cells could be detected in 15 cases of AML (62%) and that containing exon v6 alone in 17 cases (70%). Exon v3 was not detected in combination with any other exons while exon v6 could be detected in multiple larger products in seven cases (30%). Exons v4 and v5 were not detected in any of the cases tested. Exon v7 was present in five cases (21%) and in four of those, multiple bands were present. Exons v8, v9 and v10 were detected in 20 (83%), 17 (71%) and 22 (92%) cases, respectively. In the majority of cases, multiple bands containing each exon were present. It is possible that bands representing CD44 isoforms which were identified in normal bone marrow or peripheral blood mononuclear cells could be due to the presence of small numbers of contaminating normal cells. However the larger, more complex bands frequently detected in leukemic samples were not found in normal hematopoietic cells and therefore most likely originated from the leukemic population. The complexity of the patterns observed made it impossible to determine which exons were contained in individual products. The variant containing products detected in normal marrow and peripheral blood samples were frequently detected in leukemic samples, however many variant containing products which were detected in leukemic samples were not found in normal samples. Some products detected only in leukemic samples included an exon v6 containing product of approximately 950 bp and an exon v8, 
Exon specific RT-PCR
In some cases, RT-PCR and Southern blotting did not detect cDNAs containing exons that were detected by flow cytometry. In these cases RT-PCR was performed using exon-specific primers. In these experiments RT-PCR was performed using a single primer to individual exons with a primer to the constant Leukemia region. This allowed for specific amplification of variant exon containing cDNAs while distinguishing between PCR products derived from cDNA and genomic DNA. This revealed additional bands not detected by RT-PCR and Southern blotting. Generally the patterns were complex and did permit clear identification of the exon combinations present. Using this method, exons v4, v5 and v7 were detected in all cases that were positive for these exons by flow cytometry (data not shown). This suggests that the sensitivity of the RT-PCR and Southern blotting may not be sufficient to detect all physiologically relevant cDNAs. 
Analysis of variants expressed by AML blasts
In some cases overlap extension was used to clone CD44 cDNAs obtained from patients samples which contained particular exons. cDNAs containing exon v6 were cloned from two patients (Nos 16 and 26) . The v6 containing variants cloned contained exons v6-v10 and exons v6-v9. This second cDNA is the same size as the 950 bp band detected in approximately 30% of the AML cases and was not observed in normal hematopoietic cells. cDNAs containing exon v8-10 and v7-10 have also been cloned from AML patient cDNAs.
No correlation between CD44 variant expression and clinical parameters including sample source or handling, FAB classification, white blood cell count, attainment or length of remission were observed although the number of assessable cases was low.
Discussion
There is considerable evidence implicating CD44 in the interaction between hematopoietic cells and the bone marrow stroma: 7 an interaction known to be important for the controlled production of hematopoietic cells, the maintenance of the most primitive progenitor cells 29 and egress of hematopoietic cells from and homing to the bone marrow. 30, 31 The exact nature of the involvement of CD44 in these interactions is still unclear but is most likely associated with the function of CD44 as an adhesion molecule. 7 The insertion of variant exons into the membrane proximal region can modify the adhesive function of CD44 and could therefore modify the interactions between hematopoietic progenitors and the bone marrow stroma. 22, 32 Exons v8-v10 have been detected in normal hematopoietic cells. 12, 23 In addition to exons v8-v10 we have detected mRNA containing exons v3 and v6 alone in normal resting bone marrow mononuclear cells, peripheral blood lymphocytes and CD34 + progenitors. Similar findings have also been recently reported in a number of hematopoietic malignancies. 15, 16, 24 Caution needs to be applied when using CD44 variant antibodies to determine CD44 variant expression. Conflicting data has been obtained by different groups with respect to the correlation between exon v6 expression and prognosis in some cancers. Some of this discrepancy appears to result from the use of different exon v6 antibodies. 33 Legras et al 24 detected exon v6 on 73% of AML cases using the antibody VFF-18, while using antibody VFF-7 we only found 7% of cases and Khaldoyanidi et al 34 16% of cases to be positive. Legras et al 24 also detected exon v6 on 12% of normal CD34 + progenitors, which we could not detect using the VFF-7 antibody. Our data obtained using RT-PCR and Southern blotting, where 63% of AML cases studied were positive for exon v6, was similar to that obtained by flow cytometry by Legras et al. 34 However, we also detected exon v6 in all normal bone marrow and peripheral blood samples using RT-PCR and Southern blotting. Similarly, conflicting data have been reported for the expression of exon v10 on AML cells. While Ghaffari et al 23, 35 found 54% of AML cases expressed exon v10 by flow cytometry we failed to detect exon v10 on any of the AML cases tested. Our result is similar to that obtained by Khaldoyanidi et al 34 who detected exon v10 on only two of 32 cases (6%). Again we were able to detect message for CD44R2 (which contains exon v10 only) in normal as well as most leukemic samples. This could suggest that the mRNA may be present prior to the expression of the protein on the cell surface or that the level of expression is too low or in an inappropriate conformation to be detected by flow cytometry using the antibody VFF-16.
Exons v4 and v5 were detected by flow cytometry but not by RT-PCR and Southern blotting, however they were detected using exon specific RT-PCR. For RT-PCR and Southern blotting, positive and negative controls were used on all filters to confirm that the transfer and hybridization steps had worked. This suggests that very low levels of exon v4 and v5 mRNA, which were not detected by RT-PCR and Southern blotting are responsible for producing significant levels of protein. The failure of antibodies to exons v4, v5 and v7 to bind a number of cell types including normal peripheral blood and bone marrow samples and myeloid leukemic cell lines suggests that these antibodies do not bind non-specifically to myeloid cells. A recent study using the same exon v5 antibody (VFF-8) found five of 32 cases of AML (16%) to be positive, 34 a result similar to that observed in this study.
Only three mRNA species containing exons v8-v10 were detected in normal samples but in leukemic samples exons v7-v10 were observed in complex patterns of larger mRNAs. It is possible that exon containing mRNAs may have originated from contaminating activated normal lymphocytes or monocytes which are known to express some of the variants detected. However we believe this is unlikely, due to the high level of purity of the AML samples. Unfortunately it was not always possible to determine the exon combinations present in individual mRNAs and it may be necessary to clone and sequence CD44 cDNAs to clarify the exon combinations present. However, the detection of more complex patterns of CD44 variant expression in AML samples compared to normal peripheral blood, bone marrow or CD34
+ cells is reminiscent of the patterns obtained in other malignancies including gastric, renal, colonic and cervical cancers. 18, [36] [37] [38] The complex patterns of variant exon expression combined with the detection of retained introns in some malignant tissues raises the possibility that CD44 variant expression in malignant cells indicates a general loss of regulation of the splicing mechanism within these cells. [39] [40] [41] [42] Although not directly tested for, there was no evidence for the presence of retained introns in AML in our study. Aside from the possible biological consequence of CD44 variant expression the complex patterns obtained may prove to be of diagnostic, prognostic or even therapeutic value. 43 Expression of variants containing exon v6 have been related to increased metastatic potential in breast and pancreatic cancers and non-Hodgkin's lymphoma, [44] [45] [46] a poor prognosis in acute myeloid leukemia 24 and decreased aggressiveness in ovarian and oral cancers. 47, 48 In non-Hodgkin's lymphoma, the inclusion of additional variant exons with exon v6 reversed the effect seen with exon v6 alone. CD44 containing exons v6 and v7 in the one CD44 molecule have an increased repertoire of glycosaminoglycan ligands. 32 Neither exon expressed alone has this effect. These results emphasise the importance of the exon combinations rather than the effect of individual exons in the function of CD44. It is likely that neither antibody data nor RT-PCR and Southern blotting data alone will provide information relating to the function of variably spliced CD44 since neither of these techniques provide good information on exon combinations. A greater understanding of the effect of variant expression on the function of CD44 may help unravel the confusing and often contradictory information currently available on the effects of variant expression in the biology of cancers. The role of the CD44 variants detected in leukemic, but not normal samples plays in the biology of the leukemic cell is currently unknown and whether these variant proteins contribute to the malignant phenotype remains to be determined.
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